QPharma, Inc. Offers On-Demand Printing Services
* Reuters is not responsible for the content in this press release.
MORRISTOWN, N.J.--(Business Wire)-- QPharma, Inc., the industry leader in FDA Regulatory and Compliance Solutions, announced today the official release of their On-Demand Printing capabilities. This ordering tool offers QPharma`s pharmaceutical and biotechnology clients a valuable, cost-saving tool for online printing of variable data materials, such as sample request forms and disbursements, audit letters, and representative-triggered mail pieces. On-Demand Printing allows sales representatives and management to order only materials that they need, when they need it, saving time and cost over traditional printing methods. QPharma`s On-Demand Printing is a proactive approach to "going green," while eliminating costly overruns and waste of expired printed materials. On-Demand Printing specifically allows QPharma`s clients to generate customized materials as needed. The variable data printing method produces creative, personalized marketing pieces that generate customer loyalty and higher response rates when compared to the traditional generic direct mail approach. "This service is especially critical at a time when the industry is cutting back on the size of sales forces," commented Jeff Volyn, Director of Operations at QPharma. "Using On-Demand Printing, sales representatives will be able to save time and cost while maximizing their marketing efforts." About QPharma QPharma is the industry leader in FDA Regulatory and Compliance Solutions. Since 1994, the company has focused on delivering a comprehensive suite of Validation, PDMA, and Fulfillment Solutions to the FDA-regulated industries. Additional information can be found at www.qpharmacorp.com. For more information on Print-on-Demand, please contact Jessica Labita at 22 South Street, Morristown, NJ 07960, 973-656-0011, jessica.labita@qpharmacorp.com. QPharma, Inc. Jessica Labita, 973-656-0011 Fax: 973-656-0408 jessica.labita@qpharmacorp.com www.qpharmacorp.com Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.



Follow Reuters